Liver Cancer Therapeutics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

The liver cancer therapeutics market was valued at USD 3.00 Billion in 2025. It is poised to grow at a CAGR of 19.85% during the forecast period of 2026-2035, and reach USD 18.34 Billion by 2035. The market growth is driven by the rising incidence of liver cancer, increasing hepatitis infections, and growing demand for targeted therapies, supported by advancements in immunotherapy and improved early diagnosis rates globally.

Key Market Trends and Insights

• By cancer type, hepatocellular carcinoma held about 74% of the market share in the historical period.
• By therapy type, chemotherapy commanded over 30% share of the market size in the historical period.
• By country, the United States captured above 39% of the market share in the historical period.

Market Size and Forecast

• Market Size (2025): USD 3.00 Billion
• Projected Market Size (2035): USD 18.34 Billion
• CAGR (2026-2035): 19.85%

Liver Cancer Therapeutics Market Overview

The market is expanding due to rising incidence of hepatocellular carcinoma and increasing hepatitis-related cases globally. Advancements in targeted therapies and immunotherapy are improving treatment outcomes. Growing awareness and early diagnosis further support market growth. Liver cancer treatment landscape continues to evolve with strong pipeline development and increasing adoption of innovative oncology solutions worldwide. The market reached a value of approximately USD 3.00 Billion in 2025.

Liver Cancer Therapeutics Market Growth Drivers

Advancing Targeted and Immunotherapy Pipeline Driving Market Development

Rising global HCC burden and growing clinical evidence for combination regimens are major drivers of the market. The proliferation of targeted therapies directly supports market growth. For instance, in February 2026, the FDA granted fast track designation to irpagratinib, Abbisko Therapeutics' selective FGFR4 inhibitor, for previously treated HCC, strengthening the competitive pipeline and expected to accelerate patient access throughout the forecast period.

Liver Cancer Therapeutics Market Trends

Key trends shaping the market include rising adoption of immunotherapy, targeted therapies, and increasing focus on combination treatment strategies globally.

Increasing Adoption of Combination Therapies Enhancing Treatment Outcomes in the Market

Rapid adoption of dual immunotherapy combinations and targeted kinase inhibitors is reshaping the HCC treatment landscape. Expanding clinical programs and expedited FDA designations underscore strong market development potential. For instance, in April 2026, AstraZeneca's EMERALD-3 Phase III trial demonstrated that the STRIDE regimen, when combined with TACE and lenvatinib significantly improved progression-free survival in unresectable HCC. This finding validates the expanding role of immunotherapy in the liver cancer therapeutics market and supports its increased adoption during the forecast period.

Liver Cancer Therapeutics Market Segmentation

Market Breakup by Cancer Type

• Hepatocellular Carcinoma
• Cholangio Carcinoma
• Hepatoblastoma
• Others

Market Breakup by Therapy Type

• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Others

Market Breakup by Route of Administration

• Oral
• Intravenous
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Liver Cancer Therapeutics Market Share

Chemotherapy Likely to Lead the Market Segment by Therapy Type

Chemotherapy commanded over 30% share of the market size during the historical period, driven by its widespread clinical use and established efficacy. Despite emerging targeted treatments, chemotherapy remains a foundational option in treatment protocols. The market share continues to reflect reliance on conventional approaches, supported by accessibility and broad patient applicability across global healthcare systems.

Liver Cancer Therapeutics Market Analysis by Region

The United States captured above 39% of the market share in the historical period, supported by advanced oncology infrastructure and strong adoption of innovative therapies. Favorable reimbursement policies, along with high diagnosis rates, continue to contribute to its regional dominance. The market in the United States is expected to maintain its leading position over the forecast period, driven by ongoing investments in research and development and the increasing burden of liver cancer cases.

Leading Players in the Liver Cancer Therapeutics Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Bristol-Myers Squibb Company

Founded in 1887 and headquartered in New York, Bristol-Myers Squibb Company is a global biopharmaceutical leader. Its portfolio includes immunotherapy agents for hepatocellular carcinoma, thereby strengthening its oncology presence. Liver cancer therapeutics remain central to its pipeline, with ongoing research advancing combination immunotherapies for improved clinical outcomes.

Eisai Co., Ltd.

Established in 1941 and headquartered in Tokyo, Eisai Co., Ltd. focuses on oncology and neurology. Its liver cancer portfolio includes targeted therapies for hepatocellular carcinoma. The treatment of hepatocellular carcinoma remains a strategic focus, supported by global collaborations and continuous innovation in targeted oncology drug development.

Exelixis Inc

Founded in 1994 and based in Alameda, California, Exelixis Inc specializes in oncology drug development. Its portfolio includes tyrosine kinase inhibitors for advanced liver cancer. Targeted cancer therapy plays a critical role in its strategy, with ongoing clinical trials aimed at improving survival outcomes in hepatocellular carcinoma patients.

Merck & Co. Inc.

Founded in 1891 and headquartered in Rahway, New Jersey, Merck & Co. Inc. is a leading global pharmaceutical company. Its oncology portfolio includes immunotherapies used in liver cancer treatment. Immuno-oncology therapy drives its market presence, with continued expansion of checkpoint inhibitors in hepatocellular carcinoma indications.

Other key players in the market are Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Pfizer Inc., Alnylam Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., and Novartis AG.

Key Questions Answered in the Liver Cancer Therapeutics Market Report

• What was the liver cancer therapeutics market value in 2025?
• What is the liver cancer therapeutics market forecast outlook for 2026-2035?
• What major factors aid the demand for liver cancer therapeutics market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major liver cancer therapeutics market trends?
• Which cancer type is expected to dominate the market segment?
• Which therapy type is expected to dominate the market segment?
• Which route of administration is expected to dominate the market segment?
• Which distribution channel is expected to dominate the market segment?
• Which application is expected to dominate the market segment?
• Who are the key players in the liver cancer therapeutics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?